Integra LifeSciences to Showcase ENT Tech in Los Angeles
The medical technology firm will highlight its portfolio during the AAO-HNSF meeting held this October.
Updated on Oct. 16, 2026 in Allergies
Live Poll
Do you trust clinical research findings when they are sponsored by medical device companies?
Integra LifeSciences is scheduled to attend the AAO-HNSF 2026 Annual Meeting and OTO EXPO in Los Angeles, which runs from October 17 to October 20, 2026. The company will showcase its ENT technology portfolio through booth exhibitions and product demonstrations.
Why it matters
The event provides a platform for medical technology companies to present clinical advancements and engage with practitioners. Integra LifeSciences will maintain a physical presence at the conference to demonstrate its latest ENT innovations.
The ACCLARENT AERA Eustachian Tube Balloon Dilation System secured FDA clearance for pediatric patients aged eight and older in December 2023. Integra LifeSciences will be stationed at booth number 1400 during the upcoming conference.
The players
Integra LifeSciences
This is a medical technology company based in Princeton, New Jersey, that specializes in surgical and regenerative solutions.
Seilesh C. Babu
He is a medical professional and researcher who specializes in otolaryngology and otology clinical studies.
The details
Company representatives will feature product demonstrations alongside clinical research presentations, including a study led by Seilesh C. Babu. The research focuses on the impact of concurrent Eustachian tube balloon dilation on surgical outcomes for chronic ear disease.
Timeline
December 2023: ACCLARENT AERA received FDA clearance for pediatric use.
October 17, 2026: Seilesh C. Babu presents research poster 890.
October 17-20, 2026: The AAO-HNSF 2026 Annual Meeting and OTO EXPO takes place.
The Big Picture
The development of medical devices for younger populations remains heavily governed by the FDA's pediatric device labeling requirements. This event demonstrates how clinical research programs extend the reach of established surgical systems to broader patient demographics.
The expansion of the AERA system for patients eight and older increases the availability of minimally invasive treatment options for chronic ear conditions. Parents and patients should consult with specialists to determine if these procedures are appropriate based on recent clinical findings.
The takeaway
Advancements in ENT technology continue to expand treatment options for pediatric populations suffering from chronic ear disease. Practitioners are increasingly focused on clinical studies to validate the long-term benefits of balloon dilation techniques.
Further reading
For more information on the latest research in the field, explore the Allergies section of our site.
Live Poll
Do you trust clinical research findings when they are sponsored by medical device companies?
